eric

NATICK, Mass., Oct. 7, 2021 /PRNewswire/ -- AffyImmune Therapeutics, Inc., a clinical stage biotechnology company developing and deploying its Tune & Track platform for the use of CAR T cells to treat solid tumors, announced today the close of a $30 million Series A+ funding by ORI Capital (ORI). The Company's [...]

NATICK, Mass. (AUGUST 19, 2021) – AffyImmune Therapeutics, Inc., a clinical stage biotechnology company finding safe, effective ways to use CAR T cells against solid cancers, announced today that scientific co-founder Moonsoo Jin will present twice at Hanson Wade’s 6^th CAR-TCR Summit being held virtually August 30 – September 2. [...]